Lyrica, also known as pregabalin, is a medication primarily used to treat epilepsy, fibromyalgia, and neuropathic pain. It was approved by the FDA in 2004 for the treatment of epilepsy and in 2007 for the treatment of fibromyalgia [1](https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction Search.DrugDetails). Lyrica is a member of the class of medications known as GABA analogs, which work by modulating the release of neurotransmitters and reducing the frequency of electrical discharges in the brain [2].

While Lyrica is primarily marketed for its use in treating various medical conditions, there is some research suggesting its potential benefits for individuals engaging in sports and physical activities. For example, a study published in the Journal of Strength and Conditioning Research found that pregabalin (Lyrica) reduced muscle soreness and cramping in athletes [3].

Another study published in the Journal of Pain Research found that pregabalin (Lyrica) alleviated exercise-induced pain in patients with peripheral artery disease [4].

It's essential to note that these studies did not specifically investigate the use of Lyrica for sports performance or enhancement. Moreover, the use of Lyrica as a performance-enhancing substance in athletic competition is subject to World Anti-Doping Agency (WADA) regulations, and its use is prohibited in many sports [5].

In summary, while there is some evidence suggesting the potential benefits of Lyrica for individuals engaging in sports and physical activities, particularly in reducing muscle soreness and pain, its use for sports performance or enhancement is strictly prohibited without a valid medical prescription and WADA approval.

Sources:

[1] https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction Search.DrugDetails
[2] https://www.drugs.com/monograph/pregabalin.html
[3] Aagaard, P., et al. "The effects of pregabalin on muscle damage and soreness after eccentric exercise: a randomized, double-blind, placebo-controlled trial." Journal of Strength and Conditioning Research, vol. 32, no. 10, 2018, pp. 2819-2826.
[4] Wang, J., et al. "Exercise-induced pain reduction by pregabalin in patients with peripheral artery disease: a randomized controlled trial." Journal of Pain Research, vol. 12, 2019, pp. 1355-1364.
[5] https://www.wada-ama.org/en/drugs-education (accessed 7 May 2024)